Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742

Q3 FY23 results · Oct–Dec 2022

Caplin Point Laboratories reported revenue from operations of ₹372.07 crore (up 14.1% from Q3 FY22) and net profit of ₹97.39 crore (up 22.8% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	372.07	326.20	+14.1%	359.05	+3.6%
Other income	14.15	9.54	+48.3%	16.48	−14.1%
Total income	386.22	335.74	+15.0%	375.53	+2.8%
Profit before share of associates & JVs and tax	111.73	98.66	+13.2%	110.45	+1.2%
Share of profit/(loss) of associates & JVs	0.01	0.00		0.00
Net profit for the period	97.39	79.28	+22.8%	92.03	+5.8%
Attributable to shareholders of the company	97.48	74.95	+30.1%	91.67	+6.3%
EPS, basic (₹)	12.86	9.90	+29.9%	12.09	+6.4%
Net margin (%)	26.2	24.3		25.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ
Revenue from operations	130.60	128.22	+1.9%	136.95	−4.6%
Other income	29.36	8.54	+243.8%	22.45	+30.8%
Total income	159.96	136.76	+17.0%	159.40	+0.4%
Profit before tax	74.36	55.69	+33.5%	73.32	+1.4%
Net profit for the period	59.17	39.12	+51.3%	57.51	+2.9%
EPS, basic (₹)	7.80	5.17	+50.9%	7.59	+2.8%
Net margin (%)	45.3	30.5		42.0

Consolidated

Filed with BSE: 13 Feb 2023, 10:38 IST
Board meeting: 11 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Feb 2023, 10:38 IST
Board meeting: 11 Feb 2023
Period: 01 Oct 2022 to 31 Dec 2022
Review status: Unaudited
Source: XBRL filing on BSE